WO2014178078A2

WO2014178078A2 - Novel cloning, expression & purification method for the preparation of ranibizumab

Info

Publication number: WO2014178078A2
Application number: PCT/IN2014/000274
Authority: WO
Inventors: Harish Shandilya; Himanshu Gadgil; Farkade Vivek .
Original assignee: Intas Biopharmaceuticals Ltd
Current assignee: Intas Biopharmaceuticals Ltd
Priority date: 2013-04-30
Filing date: 2014-04-28
Publication date: 2014-11-06
Anticipated expiration: 2015-10-30
Also published as: US9914770B2; RU2646098C2; MX2015015188A; EP2992021A2; EP2992021A4; RU2015148746A; US20160289314A1; WO2014178078A3; ZA201508706B; CA2911087A1; MX368142B; EP2992021B1

Abstract

The present invention relates to Ranibizumab cloning, expression and production using a novel approach for better yield and biologically active protein.

Description

RELATED APPLICATIONS

This application is related to Indian Provisional Application 1 570/M UM/201 3 filed 30* ¹ Apr, 201 3 and is incorporated herein in its entirety.

FIELD OF THE INVENTION

The present invention relates to Ran ibizumab cloning, expression and production us i ng a novel approach for better yield and biological ly active protein. .

BACKGROUND OF THE INVENTION

Proteins are important as these are used to cure a number of d iseases includ ing angiogenesis (V EGF) d iabetes (e.g. Insu l in), cancers (e.g. Interferon, monoclona l antibod ies), heart attacks, strokes, cystic fibrosis (e.g. Enzymes, Blood factors), inflammation diseases (e.g. Tumor Necrosis Factors), anemia (e.g. Erythropoietin), hemophilia (e.g. Blood clotting factors) etc. One of the important chal lenges is the development of efficient and competent process for the cloning, expression and large scale purification of these proteins. Numerous processes are avai lable for the cloning, expression and large sca le purification of desired protein from the cell culture supernatants, but stil l it is difficult to clone, express and separate the desired protein from the mixture.

Vascular endothelial growth factor A (VEGF-A) is a biological component that can trigger angiogenesis, which is the growth of new blood vessels. Various diseases, inter al ia, ischem ia, anemia, peripheral vascular disease, and atherosclerotic lesions can be treated by increasing angiogenesis. This is accomplished by stimulating the up-regulation of VEG F-A, thereby leading to increased blood circulation, hence increased oxygen supply, in the diseased tissue. In the eye, however, excessive vascularization can result in blood and flu id leaking into the eye. These leaky blood vessels can contribute to macular edema and choroidal neovascularization, resulting, in the wet type of age-related macular degeneration (AMD). The result of AMD can be the loss of visual acuity or even bl indness. Therefore, control of excessive macular vascularization is important i n the treatment o f macu lar degeneration. As such, it is a goal of med ical professionals to provide a treatment for control l ing or curing A M D without inhibiting the beneficial effects of normal VEGF-A activity in the rest of the body. Ran ibizumab has been found to be an effective treatment of AMD. Ran ibizumab is a recombinant human ized IgGI kappa isotype monoclonal antibody that inh ibits VEGF activity by competitively binding to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of th is molecu le, VEGF l 10.^·; Hence, Ranibizumab prevents bind ing of VEGF-A to its principle receptors VEGFR 1 and VEGFR2 found on the surface of endothelial cel ls. This results in reduced endothel ial cell proliferation, vascular leakage, and new blood vessel formation .

LUCENTIS® is a medical formulation of Ranibizumab and des igned for intraocular i njection directly into the vitreous humor of the eye, wherei n the active i ngred ient Ran ibizu mab penetrates the internal l im iting membrane to access the subretinal space. These injections are typically given from 5 to 7 times a year to patients and in many instances are given monthly. Since the cost of treatment is very h igh and not many patients can afford it as such, there is still a need for improved cloning process and purification of the protein so that the production efficiency can be enhanced and the drug can be produced cheaper.

US6998383 discloses RANK inhibitor consisting of a TRA F-6 bind i ng domain attached to a leader sequence.

US7569384 discloses nucleic acid molecule encod ing album in fusion protein. A lso discloses vectors containing these nucleic acids, host cel l transformed with these nucleic acid vectors and methods of making the albumin fusion protein using these nucleic acids, vectors and/or host cel l .

US8597907 discloses a method for efficiently producing an industrial ly useful protein in coryneform bacteria. The present invention provides a method for efficiently producing heterologous proteins comprising culturing coryneform bacteria containing an genetic construction contain ing a promoter sequence which functions in coryneform bacteria, a nucleic acid sequence encoding a Tat system- dependent signal peptide region, and a nucleic acid sequence encoding a heterologous protein, in the direction from 5'-end to 3'-end, and secretory producing the heterologous protein by coryneform bacteria.

US5641870 discloses a process for purifying an antibody. In this process, a m ixture contain ing the antibody and contaminant is subjected to low pH hydrophobic interaction chromatography (LPH IC) optionally at low salt concentration. The antibody is eluted from the col umn in the fraction wh ich does not bind thereto. This process can be preceded and followed by other puri fication steps.

US7847071 discloses a method of purifying an antibody comprising the steps of: firstly, puri fying an antibody by means of protein A affinity chromatography wherein the protein A is a native protein A or a functional derivative thereof, secondly, loading the purified antibody comprising a protein A- contaminant, wherein said protein A-contam inant is obtained upon eluting bound antibody from sa id protein A affinity chromatography, on a first ion exchanger under cond itions wh ich al low for binding of the protein A or its derivative, thirdly, collecting the antibody loaded onto the first ion exchanger in the flow-through of the first ion exchanger whilst a contam inant protein A is bound to the first ion exchanger, wherein the first ion exchanger is an anion exchanger, further purifying the anti body by load ing on, binding to and eluting it from a second ion exchanger, and discard ing a tai l fraction of the eluate of the second ion exchanger such that a monomeric antibody fraction is enriched as a puri fied antibody pool.

WO201 1 08921 2 discloses a method for depleting impurities, in particu lar host cell proteins (HCP) and DNA from cel l culture supernatants by means of protein A chromatography using a novel washing bu ffer.

Liu et al., discussed in mAbs 2, 20 1 0, 480-499 about the basic un it operations such as harvest, Protein A affinity chromatography and additional polishing steps along with alternative processes such as floccu lation, precipitation and membrane chromatography and also covered platform approaches to purification methods development, use of high throughput screen ing methods, and o ffered a view on future developments in purification methodology as applied to monoclonal antibodies.

Refolding of inclusion body proteins into bioactive forms is cumbersome, requ ires many operational steps and most of the time results in very low recovery o f refolded protein. In the cases where a high yielding recovery process has been developed for refolding of the aggregated protein, inclusion body formation provides a straight forward strategy for recombinant protein purification. The h igher the amount of this partially folded protein that is converted into the bioactive form, the more therapeutic protein can be recovered with improved yield and at low cost from inclusion bodies of E. col i .

It is necessary to have a method for the clon ing, expression and purification of antibod ies and preferably without cost-intensive chromatographic steps as well as extensive steps. The antibody obtained by the cloning, expression and purification method accord ing to the present invention is supposed to meet the criteria for purity & yield which are set forth by the admission authorities.

OBJECT OF THE INVENTION

The principal object of the present invention is to use novel clon ing processes followed by novel protein expression and its purification procedures for rapid and efficient recovery of recom binant Ranibizumab. It is an object of the present invention to provide novel clon ing process of Ran ibizumab wh ich comprises transform ing the host cell with :

i) the vector comprising nucleic acid sequence of SEQ ID No. 1 encoding for l ight chain of Ranibizumab having an amino acid sequence as shown in SEQ ID No. 2 wherein N-terminal of the said SEQ ID No. 1 is operably linked to a unique signal sequence, start codon and an inducible promoter system

ii) transforming another host cell with another plasm id vector comprising nucleic acid sequence of SEQ ID No. 3 encoding for heavy chain of Ran ibizumab having an am ino acid sequence as shown in SEQ ID No. 4 wherein N-term inal of the said SEQ ID No. 3 is operably l inked to a un ique signal sequence, start codon and an inducible promoter system .

Another object of the present invention is to provide novel protein expression method for the preparation of Ranibizumab which comprises steps of:

i) expressing l ight & heavy chain separately in two different expression host cel ls

i i) exporting protein to the periplasmic space of the cel ls with the help of a un ique signal sequence iii) partial ly pure light and heavy chain proteins are refolded together in-vitro

Yet another object of the present invention is to provide novel protein purification method of Ranibizumab having an amino acid sequence o f S EQ. I D. No. 2 and 4, which comprises:

i) high cel l density culturing of the host cel ls in a growth med ium by maintain ing specific culture conditions

i i) expression of the protein in the form of periplasm ic inclusion bodies

i ii) protein refolding of both chains together in-vitro

iv) purification of correctly folded protein

Yet another object of the present invention is to provide improved purification process of Ranibizumab which comprises:

i) in-vitro refolding of protein

i i) performing anion exchange chromatography to separate out closely related m isfolded protein species .

iii) performing cation exchange Chromatography followed by

iv) ultra filtration/Diafiltration

Further object of the present invention is to provide improved purification process of Ranibizumab wh ich is capable to separate out even closely related misfolded protein species (>95% pure protein). Yet another object of the invention is to provide a nucleic acid sequence of SEQ ID No. 1 which encodes for l ight chain of Ranibizumab wherein N-term inal of the said S EQ I D No. 1 is operably l inked to a unique signal sequence (SEQ ID No. 5).

Yet another object of the invention is to provide a nucleic acid sequence of S EQ I D No. 3 wh ich encodes for heavy chain of Ranibizumab wherein N-terminal of the said SEQ ID No. 3 is operably l inked to a unique signal sequence (SEQ ID No. 6).

Yet another object of the invention is to provide use of un ique signal sequence contain ing the am ino acid sequence of SEQ ID No. 5 for production of anti-VEGF antibody.

Yet another object of the invention is to provide use of a un ique signal sequence containing the amino acid sequence of SEQ ID No. 6 for production of anti-VEGF antibody.

Yet another object of the invention is to provide use of a un ique signa l sequence conta in i ng the am ino acid sequence of SEQ ID No. 5 for production of light chain of Ran ibizumab.

Yet another object of the invention is to provide use of a un ique signal sequence contain ing the am ino acid sequence of SEQ ID No. 6 for production of heavy chain of Ranibizumab.

SUMMARY OF THE INVENTION

The principal aspect of the present invention is to use novel cloning processes followed by novel protein expression and its purification procedures for rapid and efficient recovery of recombinant Ranibizumab.

It is an aspect of the present invention to provide novel clon ing process of Ran ibizumab which comprises transform ing the host cel l with:

ii) transforming another host cel l with another plasm id vector comprising nucleic acid sequence of SEQ ID No. 3 encoding for heavy chain of Ranibizumab having an am i no acid sequence as shown in SEQ ID No. 4 wherein N-terminal of the said SEQ ID No. 3 is operably l inked to a unique signal sequence, start codon and an inducible promoter system .

Another aspect of the present invention is to provide novel protein expression method for the preparation of Ranibizumab which comprises steps of:

i) expressing light & heavy chain separately in two different expression host cel ls

i i) exporting protein to the periplasm ic space of the cel ls with the hel p of a un iq ue signal sequence i ii) partial ly pure light and heavy chain proteins are refolded together in-vitro

Yet another aspect of the present invention is to provide novel protein purification method of Ran ibizumab having an am ino acid sequence of SEQ. ID. No. 2 and 4, which comprises:

i) high cell density culturing of the host cel ls in a growth med ium by maintain ing speci fic culture conditions

i i) expression of the protein in the form of peri plasmic inclusion bod ies

iii) protein refolding of both chains together in-vitro

iv) purification of correctly folded protein

Yet another aspect of the present invention is to prov ide improved puri fication process of Ranibizumab which comprises:

i) in-vitro refolding of protein

ii) performing anion exchange chromatography to separate out closely related m isfolded protein species

i ii) performing cation exchange Chromatography fol lowed by

iv) ultra filtration/Diafiltration

Further aspect of the present invention is to provide improved purification process of Ranibizumab which is capable to separate out even closely related misfolded protein species (>95% pure protein).

Yet another aspect of the invention is to provide a nucleic acid sequence of SEQ ID No. 1 wh ich encodes for light chain of Ranibizumab wherein N-terminal of the said SEQ ID No. 1 is operably linked to a unique signal sequence (SEQ ID No. 5).

Yet another aspect of the invention is to provide a nucleic acid sequence of S EQ I D No. 3 wh ich encodes for heavy chain of Ranibizumab wherein N-terminal of the said SEQ ID No. 3 is operably l inked to a unique signal sequence (SEQ ID No. 6). Yet another aspect of the invention is to provide use of unique signal sequence contain ing the am ino acid sequence of SEQ ID No. 5 for production of anti-VEGF antibody.

Yet another aspect of the invention is to provide use of a unique signal sequence contain ing the am ino acid sequence of SEQ ID No. 6 for production of anti-VEGF antibody.

Yet another aspect of the invention is to provide use o f a un ique signal sequence contai n ing the am ino acid sequence of SEQ ID No. 5 for production of l ight chain of Ran ibizumab.

Yet another aspect of the invention is to provide use of a unique signal sequence containing the amino acid sequence of SEQ ID No. 6 for production of heavy chain of Ranibizumab.

BRIEF DESCRIPTION OF THE FIGURES

Fig. 1 represents expression plasm id carrying Ran ibizumab l ight chain gene construct

Fig. 2 represents expression plasmid carrying Ran ibizumab heavy chain gene construct

Fig.3 represents characterization of recombinant protein expressed using above process

Fig.4a represents CD Spectra o f properly folded Ran ibizumab- compared with Lucentis

Fig.4b represents fluorescence Spectra of properly fo lded Ranibizumab compared with Lucentis

Fig.5 represents cell based assay showing comparative potency of recombinant Ranibizumab compared with Lucentis

DETAILED DESCRIPTION OF THE INVENTION

Ranibizumab is an affinity maturated Fab fragment derived from bevacizu mab. Ran ibizumab has a h igher affinity for VEGF and also is smal ler in size, al lowing it to better penetrate the retina, and thus treat the ocular neovascularization associated with AMD (Lien and Lowman, In : Chemajovsky, 2008, Therapeutic Antibodies. Handbook of Experimental Pharmacology 1 8 1 , Springer-Verlag, Berl in Heidelberg 1 3 1 - 1 50). Ranibizumab was developed and is marketed by Genentech under the trade name Lucentis.

LUCENTIS is a sterile, colorless to pale yel low solution in a single-use glass vial . Ranibizumab, wh ich lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system in a nutrient medium containing the antibiotic tetracycline. Tetracycline is not detectable in the final product.

Unless indicated otherwise, the term "VEGF-binding molecule" includes anti-VEGF antibodies, anti- VEGF antibody fragments, "anti-VEGF antibody-like molecules" and conjugates with any of these. Antibodies include, but are not limited to, monoclonal and chimerized monoclonal antibodies. The term "antibody" encompasses complete immunoglobulins, like monoclonal antibodies produced by recombinant expression in host cells, as well as VEGF-binding antibody fragments or "antibody-like molecules", including single-chain antibodies and linear antibodies, so-called "S IPs" ("Small Modular Immunopharmaceuticals"), as e.g. described in WO02/056910. Anti-VEGF antibody-like molecules include immunoglobulin single variable domains, as defined herein. Other examples for antibody-like molecules are immunoglobulin super family antibodies (IgSF), or CDR-grafted molecules.

"VEGF-binding molecule" refers to both monovalent VEGF-binding molecules (i.e. molecules that bind to one epitope of VEGF) as well as to bi- or multivalent binding molecules (i.e. binding molecules that bind to more than one epitope, e.g. "biparatopic" molecules as defined hereinbelow).

Signal sequence refers to a sequence present on the N-terminal side of a secretory protein precursor but absent in the naturally-occurring mature protein, and a "signal peptide" refers to a peptide cleaved from such a protein precursor. In general, a signal sequence is cleaved by a protease (typically referred to as a signal peptidase) when secreted extracellularly. Although such signal peptides have constant, common features in their sequences among biological species, a signal peptide which exhibits a secretory function in a certain biological species does not necessarily exhibits-secretory function in another biological species.

Inclusion bodies are dense electron-refractile particles Of aggregated protein found in both the cytoplasmic and periplasmic spaces of E. coli during high-level expression of heterologous protein, it is generally assumed that high level expression of non-native protein (higher than 2% of cellular protein) and highly hydrophobic protein is more prone to lead to accumulation as inclusion bodies in E. coli. In the case of proteins having disulfide bonds, formation of protein aggregates as inclusion bodies is anticipated since the reducing environment of bacterial cytosol inhibits the formation of disulfide bonds.

Inclusion bodies have higher density (~1.3 mg ml-1) than many of the cellular components, and thus can be easi ly separated by high-speed centrifugation after cell d isruption. Expression o f recombi nant proteins as inclusion bodies in bacteria is one of the most efficient ways to produce cloned proteins, as long as the inclusion body protein can be successfully refolded. Aggregation is the lead ing cause of decreased refolding yields.

Protein refolding refers to the process by wh ich a protein structure assumes its functional shape or conformation. It is the physical process by wh ich a polypeptide folds into its characteristic and functiona l three-dimensional structure from random coi l. Each prote in exists as an un folded polypeptide or random coi l when translated from a sequence of m RNA to a l inear chain of amino acids. This polypeptide lacks any stable (long-lasting) three-dimensional structure. A m ino acids interact with each other to produce a well-defined three-dimensional structure, the folded protein, known as the native state. The resulting three-dimensional structure is determined by the amino acid sequence. Insoluble, inactive inclusion bodies are frequently formed upon recombinant protein production in transformed microorganisms. These inclusion bodies, which contain the recombinant protein in an high ly enriched form, can be isolated by solid/liquid separation. After solubilization, native proteins can be generated from the inactive material by using in vitro folding techniques.

The present invention provides new refolding procedure for Ran ibizumab comprising effic ient in vitro reconstitution of complex hydrophobic, multidomain, ol igomeric, or high ly d isu lfide-bonded proteins. These protocols take into account process parameters such as protein concentration, catalys is of d isuffide bond formation, temperature, pH, and ionic strength, as wel l as specific solvent ingred ients that reduce unproductive side reactions.

Clone refers to a DNA sequence, such as a gene, that is transferred from one organ ism to another and replicated by genetic engineering techniques. The present invention comprises genes of heavy and l ight chain of Ranibizumab with desired modifications for cloning on both the ends. The gene sequences are optimized for better protein expression in E. coli. The synthetic constructs are made so as to have a bacterial leader signal sequence at the N-terin inal fol lowed by sequences of gene of i nterest and two translation stop codons in the end. These signal sequences are selected on the basis of their abil ity so that they can transport maximum protein in the periplasm of the cell . The signal sequence chosen was taken from a natural bacterial gene.

The main embodiment of the present invention is to use novel cloning processes fol lowed by novel protein expression and its purification procedures for rapid and efficient recovery of recombinant Ranibizumab.

It is yet another embodiment of the present invention to provide novel cloning process of Ranibizumab which comprises transforming the host cell with:

i) the vector comprising nucleic acid sequence of SEQ ID No. 1 encoding for light chain of Ranibizumab having an amino acid sequence as shown in SEQ ID No.2 wherein N-terminal of the said SEQ ID No. 1 is operably linked to a unique signal sequence, start codon and an inducible promoter system

ii) transforming another host cell with another plasm i^'d vector comprising nucleic acid sequence of SEQ fD No.3 encoding for heavy chain of Ranibizumab having an amino acid sequence as shown in SEQ ID No.4 wherein N-terminal of the said SEQ ID No.3 is operably linked to a unique signal sequence, start codon and an inducible promoter system.

Another embodiment of the present invention is to provide novel protein expression method for the preparation of Ranibizumab which comprises steps of:

i) expressing light & heavy chain separately in two different expression host cells

ii) exporting protein to the periplasmic space of the cells with the help of a unique signal sequence iii) partially pure light and heavy chain proteins are refolded together in-vitro.

Another embodiment of the present invention is to provide novel protein purification method of Ranibizumab having an amino acid sequence of SEQ. ID. No.2 and 4, which comprises:

i) high cell density culturing of the host cells in a growth medium by maintaining specific culture conditions

ii) expression of the protein in the form of periplasmic inclusion bodies

iii) protein refolding of both chains together in-vitro

iv) purification of correctly folded protein

Yet another embodiment of the present invention is to provide improved purification process of Ranibizumab which comprises:

i) in-vitro refolding of protein

ii) performing anion exchange chromatography to separate out closely related misfolded protein species

iii) performing cation exchange Chromatography followed by

iv) ultra filtration/Diafiltration

Yet another embodiment of the present invention is to provide improved purification process of Ranibizumab which is capable to separate out even closely related misfolded protein species (>95% pure protein).

Yet another embodiment of the invention is to provide a nucleic acid sequence of SEQ ID No. I which, encodes for light chain of Ranibizumab wherein N-terminal of the said SEQ ID No. 1 is operably linked to a unique signal sequence (SEQ ID No.5).

Yet another embodiment of the invention is to provide a nucleic acid sequence of SEQ ID No.3 which encodes for heavy chain of Ranibizumab wherein N-terminal of the said SEQ ID No.3 is operably linked to a unique signal sequence (SEQ ID No.6).

Yet another embodiment of the invention is to provide use of unique signal sequence containing the amino acid sequence of SEQ ID No.5 for production of anti-VEGF antibody.

Yet another embodiment of the invention is to provide use of a unique signal sequence containing the amino acid sequence of SEQ ID No.6 for production of anti-VEGF antibody.

Yet another embodiment of the invention is to provide use of a unique signal sequence containing the amino acid sequence of SEQ ID No.5 for production of light chain of Ranibizumab.

Yet another embodiment of the invention is to provide use of a unique signal sequence containing amino acid sequence of SEQ ID No.6 for production of heavy chain of Ranibizumab.

Light Chain Nucleotide Sequence (SEQ ID NO: 1)

5' GAGCT CCA rGGAGTTTTTCAAAAAGACGGCACTTGCCGCACTGGTTATGGGTTTTAGTGGTGCAGC AT G

GCCGATATCCAGCTGACCCAGAGCCCGAGCAGCCTGAGCGCAAGCGTTGGTGATCGTGTTACCATTACCTG

TAGCGCAAGCCAGGATATTAGCAATTATCTGAATTGGTATCAGCAGAAACCGGGTAAAGCACCGAAAGTTC

TGATTTATTTTACCAGCAGCCTGCATAGCGGTGTTCCGAGCCGTTTTAGCGGTAGCGGTAGTGGCACCGAT

TTTACCCTGACCATTAGCAGCCTGCAGCCGGAAGATTTTGCAACCTATTATTGTCAGCAGTATAGCACCGT

TCCGTGGACCTTTGGTCAGGGCACCAAAGTTGAAATTAAACGTAGCGTTGCAGCACCGAGCGTTTTTATTT

TTCCGCCTAGTGATGAACAGCTGAAAAGCGGCACCGCAAGCGTTGTTTGTCTGCTGAATAATTTTTATCCG

CGTGAAGCAAAAGTGCAGTGGAAAGTTGATAATGCACTGCAGAGCGGTAATAGCCAAGAAAGCGTTACCGA

ACAGGATAGCAAAGATAGCACCTATAGCCTGAGCAGCACCCTGACCCTGAGCAAAGCAGATTATGAAAAAC

ACAAAGTGTATGCCTGCGAAGTTACCCATCAGGGTCTGAGCAGTCCGGTTACCAAAAGTTTTAATCGTGGC

GAATGCTAATAGAAGCTTGGTACC 3' Light Chain Amino acid Sequence (SEQ ID NO: 2)

DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQ PG APK VLIYFTSSLHSGVPSRFSGSGSGTDFTLTISS LQ PEDFAT Y V CQQ Y S TVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQL SGTASVVCLLN NFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Heavy Chain Nucleotide Sequence (SEQ ID NO: 3)

5' GAGCTCATATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGC GATGGCCGAAGTTCAGCTGGTTGAAAGCGGTGGTGGTCTGGTTCAGCCTGGTGGTAGCCTGCGTCTGAG CTGTGCAGCAAGCGGTTATGATTTTACCCATTATGGTATGAATTGGGTTCGTCAGGCACCGGGTAAAGG TCTGGAATGGGTTGGTTGGATTAATACCTATACCGGTGAACCGACCTATGCAGCAGATTTTAAACGTCG TTTTACCTTTAGCCTGGATACCAGCAAAAGCACCGCATATCTGCAGATGAATAGCCTGCGTGCAGAAGA TACCGCAGTTTATTATTGTGCCAAATATCCGTATTACTATGGCACCAGCCACTGGTATTTCGATGTTTG GGGTCAGGGCACCCTGGTTACCGTTAGCAGCGCAAGCACCAAAGGTCCGAGCGTTTTTCCGCTGGCACC GAGCAGCAAAAGTACCAGCGGTGGCACAGCAGCACTGGGTTGTCTGGTTAAAGATTATTTTCCGGAACC GGTTACCGTGAGCTGGAATAGCGGTGCACTGACCAGCGGTGTTCATACCTTTCCGGCAGTTCTGCAGAG CAGCGGTCTGTATAGCCTGAGCAGCGTTGTTACCGTTCCGAGCAGCAGCCTGGGCACCCAGACCTATAT TTGTAATGTTAATCATAAACCGAGCAATACCAAAGTGGATAAAAAAGTTGAGCCGAAAAGCTGCGATAA AACCCATCT GT AAT AG GGTACC 3'

Heavy Chain Amino acid Sequence (SEQ ID NO: 4)

EVQLVESGGGLVQPGGSLRLSCAASG YD FT HYGMNWVRQAPG KGLEW VG INTYTGEPT YAADFKRRFTFSLDTSKSTA YLQMNSL RAEDTAVYYCAK YPYYYGTSH W YFD VW G QGT LYT VSS AST KG P SV FPL APSSKSTSGGT AA LGC L VKD Y FPE PV T YS W SG ALTSG H TFPA VLQSSGLYSLSS VVTVPSSSLGTQT YIC VN HK PSNTKVDK KVEPKSCDKTHL

The amino acid sequence of the unique signal sequence for light chain of Ranibizumab is:

MEFFKKTALAALVMGFSGAALA (SEQ ID No: 5)

The amino acid sequence of the unique signal sequence for heavy chain of Ranibizumab is:

MKYLLPTAAAGLLLLAAQPAMA (SEQ ID No: 6) The invention wi l l now be further described by the fol lowing examples, wh ich are i l lustrative rather than l imiting.

Example 1

Generation of pCDL18-LC vector for light chain of Ranibizumab

Bacterial expression vector for l ight chain of Ranibizumab was generated by cloning l ight chain of Ranibizumab along with a signal sequence (SEQ ID No: 1 ) at the 5 ' end into the Nco l/H indl H site in multiple cloning site (MCS) of pCDL l 8-LC vector.

Key components of synthetic gene cassette and schematic design are as given below.

Generation of pCDL18-HC vector for heavy chain of Ranibizumab

Bacteria! expression vector for heavy chain of Ranibizumab was generated by cloning heavy chain Ran ibizumab along with a signal sequence (SEQ \D No: 3) at the 5 ' end into the Ndel/Xho l site pCDL 1 8-HC vector.

Example 2

Transformation of light chain gene in BL21 (DE3)

pSR04 vector carrying expression construct for light chain gene (pCDL l 8-LC) was transformed in BL2 1 (DE3) and recombinant clones were selected. The transformants were plated on LB agar plates contain ing kanamycin (30 ng/ml) for selection. Protein expression analysis was also performed after inducing the cells with 1 mM IPTG for 4 h in a shake flask. Whole cell lysate and extracellular protein samples were analyzed for clone selection.

Transformation of heavy chain gene in BL21 (DE3) pS R02 vector carrying expression construct for heavy chain gene (pCDL 1 8-HC) was transformed in BL21 (DE3) and recombinant clones were selected. The transformants were plated on LB agar plates containing ampicillin for selection. Protein expression ana lysis was also performed after inducing the cells with 1 mM IPTG for 4 h in a shake flask. Whole cel l lysate and extracellular protein samples were analyzed for clone selection.

Exam ple 3

General expression of light & heavy chain separately in two different expression host cells in .coli

To maximize the desired protein expression the l ight and heavy cha i ns of Ran ibizii inab were cloned into two separate vector systems and transformed individua l ly i n two d i fferent E. col i cel ls. The protein expression is derived from T7 promoter system. Both these constructs are carried in by these high copy number plasmids and capable of expressing protein in a tightly regu lated manner.

The overexpressed recombinant proteins are purified and characterized. The first 1 0 residues at the N- tenn inal were confirmed to be DIQLTQSPSS for light chain and EVQLVESGGG for the heavy chain, wh ich is the authentic start sequence of both the chains. A clear and unambiguous signa l was obtai ned for al l the I 0 residues.

Exam ple 4

Generation of targeted protein in form of periplasm inclusion bodies

The recombinant E.coli cel ls were cultivated in the shake f!asj s (seed flasks) for inoculum preparation and for production, the inocu lum obtained from seed flask was transferred to production fermenter and cultured for 25 h in fed batch mode. During fermentation, the cel ls were provided with air and oxygen by means of sparging. The growth of the cells was maintained by control led add ition of feed (Nutrient supplements) in pH stat mode, the pH was maintained by supplying glucose and n itrogen in feed to reduce the pH of the batch. Base (NaOH) was used to increase the pH of the batch as needed. Cel ls were induced with IPTG at 20th hour of batch age and the fermentation is carried out for another 5 hours. The targeted protein is produced in the form of periplasm ic IBs. For light chain the cell culture density (OD600) at harvest was -50 and biomass obtained from that was around IQOg/L, which yielded around 25g IBs/L.

Similarly for heavy chain the cell culture density (OD600) at harvest was -100 and biomass obtained was around 155g/L which yielded around 33g FBs/L.

Example 5

Refolding of light and heavy chain together

25 g of LC and HC each were solubilized separately in 500 mL of solubilization buffer containing 6 M GuHCI and pooled in 1 :1 ratio. Pooled SIB was reduced with 4mM of DTT for 1 h. Reduced LC and HC pool was subjected to oxidation with 10 mM cystine and incubated for 3 h. Reduced and oxidized SIB were diluted 25 times in the refolding buffer (100 mM Tris, 0.6 M Arginine, 5 % Sorbitol, 2 mM EDTA, pH 9.0) by slow addition. The 0.6 mM of cystine and 0.75 mM of cysteine was added to the refolding mixture and reaction was incubated at (2-8)°C for - 5 days! Refolding output was concentrated using 10 kDa membrane and diafiltered against 50 mM Tris buffer, pH 9.0.

Yield and purity after refolding: Properly folded Ranibizumab yield after refolding was around 18% of the total protein.

Example 6

Purification for properly folded protein

Refolding output was concentrated using 10 kDa membrane and diafiltered against 50 mM Tris buffer pH 9.0. Diafiltration output was loaded on Q Sepharose FF resin in binding mode and protein was eluted out by reducing the pH to 6.7 in linear gradient in 10 CV from 0,% B to 100 % B. Q Sepharose Output was loaded on SP Sepharose HP resin at pH 5.0. Protein was eiuted out by increasing salt concentration as follows 20 % step followed by 20 % to 50 % gradient and finally a 100 % step gradient. Pooled fractions were concentrated and diafiltered against the formulation buffer. using a 10 kDa membrane.

Yield of final product after purification: The overall protein purification process recovery was around 9% with a purity level of >99%.

Claims

WE CLAiM,

1. A polynucleotide sequence of SEQ ID No. 1 encoding for a unique signal sequence of SEQ ID No.5 and the light chain of Ranibizumab of SEQ ID No.2 wherein N-terminal of the said SEQ ID No.2 is operably linked to a unique signal sequence of SEQ ID No.5.

2. A polynucleotide sequence of SEQ ID No.3 encoding for a unique signal sequence of SEQ ID No.6 and the heavy chain of Ranibizumab of SEQ ID No.4 wherein N-terminal of the said SEQ ID No.4 is operably linked to a unique signal sequence of SEQ ID No.6.

3. Use of a unique signal sequence comprising the amino acid sequence of SEQ ID No.5 for production of anti-VEGF antibody.

4. Use of a unique signal sequence comprising the amino acid sequence of SEQ ID No.6 for production of anti-VEGF antibody.

5. Use of a unique signal sequence comprising the amino acid sequence of SEQ ID No.5 for production of light chain of Ranibizumab.

6. Use of a unique signal sequence comprising the amino acid sequence of SEQ ID No.6 for production of heavy chain of Ranibizumab.

7. A recombinant vector comprising the nucleic acid sequence of SEQ ID No. 1 encoding for the light chain of Ranibizumab as claimed in claim 1.

8. A recombinant vector comprising the nucleic acid sequence of SEQ ID No.3 encoding for the heavy chain of Ranibizumab as claimed in claim 2.

9. A host cell comprising the recombinant vector as claimed in claim 7 containing the nucleotide sequence encoding for the light chain of Ranibizumab as claimed in claim I .

10. A host cell comprising the recombinant vector as claimed in claim 8 containing the nucleotide

!6

10. A host cell comprising the recombinant vector as claimed in claim 8 containing the nucleotide sequence encoding for the heavy chain of Ran ibizumab as cla imed in cla im 2.

I 1 . A novel clon ing process for the preparation of Ranibizumab comprising transform i ng the host cel l with:

a) the vector comprising nucleic acid sequence of SEQ I D No. 1 encod ing for l ight chain of Ranibizumab having an amino acid sequence as shown in SEQ ID No. 2 wherein N-term inal of the said SEQ ID No. 1 is operably linked to a unique signal sequence, start codon and an inducible promoter system

b) transforming another host cell with another plasrn id vector comprising nucleic acid sequence of SEQ ID No. 3 encoding for heavy chain of Ran ibizumab having an am ino acid sequence as shown in SEQ ID No. 4 wherein N-term inal of the said SEQ TD No. 3 is operably l inked to a unique signal sequence, start codon and an inducible promoter system .

1 2. A process for the production of l ight chain of Ran ibizumab as claimed in claim I 1 wherein the process comprises

a) transforming the host cel l with the vector as claimed in claim 7

b) culturing the high cel l density host cell in a growth med ium by maintain ing specific culture composition

c) expressing the light chain separately in a host cel l as claimed in claim 9

d) exporting light chain protein to the periplasmic space of the cells with the help of a unique signal sequence.

1 3. A process for the production of heavy chain o f Ranibizumab as claimed in claim I I wherein the process comprises:

a) transforming the host cell with the vector as claimed in claim 8

b) cu lturing the high cel l density host cel l in a growth medium by maintaining specific culture composition

c) expressing the heavy chain separately in a host cel l as claimed in claim 1 0

d) exporting heavy chain protein to the periplasm ic space of the cel ls with the help o f a unique signal sequence.

14. A novel expression process for the production of l ight cha in and heavy chain of Ran ibizumab having amino acid sequences of SEQ ID No. 2 and SEQ I D No. 4 respectivy wherei n the process comprises: a) Separately culturing the host cel ls carrying the genes for the l ight chai n and heavy chai n of Ranibizumab in a growth medium by maintaining speci fic culture composition

b) Expression of the light and heavy chain in the form of periplasm ic inclusion bodies

c) Solubil ization of the inclusion bodies

d) In-vitro refolding of the solubilized light chain and heavy chai n of Ran ibizumab and clarification. 5. A novel process comprising the reduction, oxidation and subsequent in-vitro refolding of the solubilized inclusion bodies to recover biological ly active Ranibizumab. 6. A process for the purification of Ranibizumab obtained by the process as claimed in cla im 1 5, wherein the purification process comprises the following steps:

a) Ultrafltration & diafiltration - I

b) Anion exchange chromatography

c) Cation exchange chromatography

d) Ultrafltration & diafiltration - II

e) 0.2 μιη filtration.